What side effects can be expected with bevacizumab, and which are most common and bothersome to patients? What serious side effects might occur with bevacizumab?
For the most part, bevacizumab is exceptionally well-tolerated. The notable toxicity that we already recognize is hypertension, namely modest elevation in blood pressure typically occurring over the course of weeks to months of administration. Nothing we see immediately after administration of the drug. Moreover, that's normally well-treated with any of the standard oral anti-hypertensive medications. I often use the ACE inhibitors in conjunction with patients who get hypertension, but ultimately the rates of patients who get hypertension are 10% of patients, 20% at most, but easily treated with standard remedies.
Beyond hypertension, there are some things to look out for. Proteinuria can occur early in patients who are on bevacizumab for months, so it is recommended you check urine for protein periodically, but the rates of proteinuria are pretty low. The only circumstance to which you would likely discontinue bevacizumab would be if there were 3+ proteinuria, and even then you could restart if the proteinuria diminishes again.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More